NCT07053462Source recordAI-normalized
Phase 1/2, Single-Arm, Open-Label Trial to Evaluate the Safety, Feasibility, and Immunogenicity of Ex Vivo CRISPR-Cas9 Gene-Edited Donor Kidneys (Knockout of HLA-A, HLA-B, and CIITA) in Human Renal Transplant Recipients
The trial, sponsored by the American Organ Transplant and Cancer Research Institute LLC, aims to evaluate the safety and feasibility of CRISPR-Cas9 gene-edited donor kidneys in renal transplant recipients. This innovative approach targets key HLA genes to reduce immunogenicity, potentially transforming kidney transplantation by lowering rejection rates and reliance on immunosuppressants. The market for kidney transplantation is significant, with a growing demand for improved graft survival and reduced complications associated with current immunosuppressive therapies. If successful, this trial could position the sponsor as a leader in the emerging field of gene-edited organ transplantation, attracting interest from investors and partners in the biopharmaceutical sector. However, the trial's geographic limitation to China may impact broader market applicability and scalability.
AI analysis
Indication: End-Stage Renal Disease
Modality: gene therapy
Target: HLA-A, HLA-B, and CIITA genes involved in immune recognition and graft rejection.
Sponsor: AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
Source URL: ClinicalTrials.gov
Source updated: Jul 08, 2025
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: gene therapy
View original source fields
Condition raw: End-Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Renal Disease With Renal Transplant, Kidney Transplant Rejection, Kidney Tumor, Kidney Failure, Kidney Ischemia
Condition normalized: End-Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Renal Disease With Renal Transplant, Kidney Transplant Rejection, Kidney Tumor, Kidney Failure, Kidney Ischemia
Modality raw: gene therapy
Modality normalized: gene therapy
Target raw: HLA-A, HLA-B, and CIITA genes involved in immune recognition and graft rejection.
Target normalized: HLA-A, HLA-B, and CIITA genes involved in immune recognition and graft rejection.
NCT05565248Source recordAI-normalized
An Open-Label, First-in-Human Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D)
CRISPR Therapeutics AG is advancing VCTX211, a combination product aimed at treating Type 1 Diabetes Mellitus (T1D) through innovative gene editing technology. The asset is positioned in a competitive landscape with a growing focus on cell therapies and gene editing for autoimmune diseases. The termination of the trial indicates a strategic pivot to follow-up studies (VCTX-201), which may enhance patient outcomes and data robustness. The T1D market is substantial, with increasing demand for novel therapies that offer improved glycemic control and reduced reliance on exogenous insulin. The collaboration with ViaCyte adds credibility and expertise in cell therapy, potentially strengthening market positioning.
AI analysis
Indication: Diabetes Mellitus
Modality: gene therapy
Target: Allogeneic pancreatic endoderm cells (PEC211) genetically modified using CRISPR/Cas9 to promote immune evasiveness and survival.
Sponsor: CRISPR Therapeutics AG
Source URL: ClinicalTrials.gov
Source updated: May 07, 2026
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: gene therapy
View original source fields
Condition raw: Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases
Condition normalized: Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases
Modality raw: gene therapy
Modality normalized: gene therapy
Target raw: Allogeneic pancreatic endoderm cells (PEC211) genetically modified using CRISPR/Cas9 to promote immune evasiveness and survival.
Target normalized: Allogeneic pancreatic endoderm cells (PEC211) genetically modified using CRISPR/Cas9 to promote immune evasiveness and survival.
NCT04557436Source recordAI-normalized
Phase 1, Open Label Study of CRISPR-CAR Genome Edited T Cells (PBLTT52CAR19) in Relapsed /Refractory B Cell Acute Lymphoblastic Leukaemia
The PBLTT52CAR19 asset, developed by Great Ormond Street Hospital for Children NHS Foundation Trust, targets relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL) in pediatric patients. Given the high unmet need in this patient population, the potential for PBLTT52CAR19 to secure molecular remission prior to allogeneic stem cell transplantation positions it favorably in the CAR-T therapy market. The asset's innovative use of CRISPR technology for genome editing may provide a competitive edge over traditional CAR-T therapies, particularly in terms of safety and efficacy. The completion of this Phase 1 trial will be critical for advancing to larger studies and attracting potential partnerships or acquisitions from larger biopharma entities focused on oncology.
AI analysis
Indication: B Acute Lymphoblastic Leukemia
Modality: gene therapy
Target: CD19+ B cells, utilizing CRISPR-CAR genome editing to modify T cells for enhanced anti-leukemic activity.
Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust
Source URL: ClinicalTrials.gov
Source updated: Mar 07, 2024
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: gene therapy
View original source fields
Condition raw: B Acute Lymphoblastic Leukemia
Condition normalized: B Acute Lymphoblastic Leukemia
Modality raw: gene therapy
Modality normalized: gene therapy
Target raw: CD19+ B cells, utilizing CRISPR-CAR genome editing to modify T cells for enhanced anti-leukemic activity.
Target normalized: CD19+ B cells, utilizing CRISPR-CAR genome editing to modify T cells for enhanced anti-leukemic activity.
NCT02810444Source recordAI-normalized
An Open-label, Prospective, Multicenter Study Investigating Clinical Efficacy, Safety, and Pharmacokinetic Properties of the Human Normal Immunoglobulin for Intravenous Administration BT595 as Replacement Therapy in Patients With Primary Immunodeficiency Disease (PID)
This Phase III clinical study is to test efficacy, safety and pharmacokinetics of BT595 in treating patients with Primary Immunodeficiency (PID)
AI analysis
Indication: Primary Immunodeficiency Disease
Modality: gene therapy
Target: IgG Next Generation (BT595)
Sponsor: Biotest
Source URL: ClinicalTrials.gov
Source updated: Jul 20, 2023
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: gene therapy
View original source fields
Condition raw: Primary Immunodeficiency Disease
Condition normalized: Primary Immunodeficiency Disease
Modality raw: gene therapy
Modality normalized: gene therapy
Target raw: IgG Next Generation (BT595)
Target normalized: IgG Next Generation (BT595)
NCT00104650Source recordAI-normalized
A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous Bisphosphonates
The purpose of this trial is to determine the effectiveness of AMG 162 in reducing urinary N-telopeptide in advanced cancer subjects with bone metastases.
AI analysis
Indication: Bone Metastases in Men With Hormone-Refractory Prostate Cancer
Modality: gene therapy
Target: AMG 162 180 mg (SC) q 12 weeks, IV Bisphosphonate q 4 weeks, AMG 162- 180 mg q 4 weeks
Sponsor: Amgen
Source URL: ClinicalTrials.gov
Source updated: Jan 24, 2011
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: gene therapy
View original source fields
Condition raw: Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
Condition normalized: Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
Modality raw: gene therapy
Modality normalized: gene therapy
Target raw: AMG 162 180 mg (SC) q 12 weeks, IV Bisphosphonate q 4 weeks, AMG 162- 180 mg q 4 weeks
Target normalized: AMG 162 180 mg (SC) q 12 weeks, IV Bisphosphonate q 4 weeks, AMG 162- 180 mg q 4 weeks
NCT05559801Source recordAI-normalized
A Phase 1/2 Study to Examine the Safety and Preliminary Efficacy of Mesenchymal Stromal Cells on Linear Growth and Bone Health Parameters in Children With Type 3 Osteogenesis Imperfecta (OI)
This is a Phase 1/2 study to determine the safety and efficacy of allogeneic (third party), bone-marrow derived mesenchymal stromal cells (MSCs) for the treatment of Osteogenesis Imperfecta (OI) Type 3. It will evaluate this by looking at whether there are treatment related infusion reactions, and assessing linear growth rates and bone health, both of which are impaired in patients ages 3-10 with Osteogenesis Imperfecta Type 3. This is a single-site non-randomized clinical trial, that will take place at Children's Healthcare of Atlanta (CHOA) at Egleston and Emory Children's Center.
AI analysis
Indication: Osteogenesis Imperfecta
Modality: gene therapy
Target: Bone marrow-derived mesenchymal stromal cells (MSCs)
Sponsor: Emory University
Source URL: ClinicalTrials.gov
Source updated: May 08, 2026
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: gene therapy
View original source fields
Condition raw: Osteogenesis Imperfecta, Osteogenesis Imperfecta Type III
Condition normalized: Osteogenesis Imperfecta, Osteogenesis Imperfecta Type III
Modality raw: gene therapy
Modality normalized: gene therapy
Target raw: Bone marrow-derived mesenchymal stromal cells (MSCs)
Target normalized: Bone marrow-derived mesenchymal stromal cells (MSCs)
NCT04115774Source recordAI-normalized
Registry of Osteogenesis Imperfecta That Collects Clinical, Functional, Genetic, Genealogical, Imaging, Surgical, Quality of Life Data. Data is Linked to Patients Biological Samples, When Available
ROI is a retrospective and prospective registry, finalized for care and research purposes. It is articulated in main sections - strongly related and mutually dependent on each other - corresponding to different data domains: personal information, clinical data, genetic data, genealogical data, surgeries, etc. This approach has been developed to corroborate and integrate data from different sources evaluating several aspects of diseases and to correlate genetic background and phenotypic outcomes, in order to better investigate diseases pathophysiology. Due to legal requirements, institutional directives and organizational issues, we are unable to include individuals residing outside Italy in the registry at this time. We are currently engaged in the preparation of a recruitment process for individuals residing outside Italy.
AI analysis
Indication: Osteogenesis Imperfecta
Modality: gene therapy
Target: bisphosphonates
Sponsor: Luca Sangiorgi
Source URL: ClinicalTrials.gov
Source updated: Nov 20, 2025
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: gene therapy
View original source fields
Condition raw: Osteogenesis Imperfecta
Condition normalized: Osteogenesis Imperfecta
Modality raw: gene therapy
Modality normalized: gene therapy
Target raw: bisphosphonates
Target normalized: bisphosphonates
NCT07287241Source recordAI-normalized
Evaluation of Cardiac Function and Morphology in Individuals With Osteogenesis Imperfecta: Prospective Observational Study
This prospective observational investigation will examine the incidence and progression of cardiologic findings in individuals with OI across different age groups. Cardiopulmonary complications are recognized as major contributors to morbidity and mortality in adults with OI, although life expectancy has significantly improved in recent years due to medical advancements. By systematically evaluating cardiovascular involvement in this population, the study aims to generate clinically relevant evidence to inform early cardiologic screening strategies and support the development of harmonized and targeted management approaches, ultimately improving clinical practice and the quality of life of individuals living with OI.
AI analysis
Indication: Osteogenesis Imperfecta (OI)
Modality: gene therapy
Target: Imaging evaluation, Echocardiography
Sponsor: Istituto Ortopedico Rizzoli
Source URL: ClinicalTrials.gov
Source updated: Dec 17, 2025
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: gene therapy
View original source fields
Condition raw: Osteogenesis Imperfecta (OI), Osteogenesis Imperfecta
Condition normalized: Osteogenesis Imperfecta (OI), Osteogenesis Imperfecta
Modality raw: gene therapy
Modality normalized: gene therapy
Target raw: Imaging evaluation, Echocardiography
Target normalized: Imaging evaluation, Echocardiography
NCT03066258Source recordAI-normalized
A Phase I/IIa (Phase 1/Phase 2a), Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD)
Excessive vascular endothelial growth factor (VEGF) plays a key part in promoting neovascularization and edema in neovascular (wet) age-related macular degeneration (nAMD). VEGF inhibitors (anti-VEGF), including ranibizumab (LUCENTIS®, Genentech) and aflibercept (EYLEA®, Regeneron), have been shown to be safe and effective for treating nAMD and have demonstrated improvement in vision. However, anti-VEGF therapy is administered frequently via intravitreal injection and can be a significant burden to the patients. RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein. The long-term, stable delivery of this therapeutic protein following a 1 time gene therapy treatment for nAMD could potentially reduce the treatment burden of currently available therapies while maintaining vision with a favorable benefit:risk profile.
AI analysis
Indication: Neovascular Age-related Macular Degeneration
Modality: gene therapy
Target: RGX-314
Sponsor: REGENXBIO Inc.
Source URL: ClinicalTrials.gov
Source updated: May 16, 2023
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: gene therapy
View original source fields
Condition raw: Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration
Condition normalized: Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration
Modality raw: gene therapy
Modality normalized: gene therapy
Target raw: RGX-314
Target normalized: RGX-314
NCT03243149Source recordAI-normalized
Neurofeedback With Real-Time fMRI for Treatment of Posttraumatic Stress Disorder
PTSD is a debilitating and costly condition and currently available treatment options have risks and limitations that necessitate development of novel interventions. Collectively, the functional brain imaging reports suggest that patients with PTSD, especially those with the re-experiencing and hypervigilence phenotype, show ventromedial PFC hypoactivation and amygdala hyperactivation in response to symptom provocation, and that treatment, when successful is associated with reduced amygdala and increased ventromedial PFC activation. This project is guided by a neurocircuit model of PTSD dysfunction in which abnormalities in fronto-limbic imbalance, which diminishes capacity for fear extinction learning, and produces PTSD symptoms of re-experiencing and hyperarousal. Thus, our studies aim to bridge the translational gap between theoretical and neurobiological models of PTSD to implementation of clinical practice. The Target Engagement and Dosing Phase of this project, which is a pilot study, will demonstrate target engagement and its association with laboratory measures of PTSD-relevant neural processes.
AI analysis
Indication: PTSD
Modality: gene therapy
Target: fMRI - GE Medical System
Sponsor: Duke University
Source URL: ClinicalTrials.gov
Source updated: Dec 21, 2022
Ingested: Jun 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: gene therapy
View original source fields
Condition raw: PTSD
Condition normalized: PTSD
Modality raw: gene therapy
Modality normalized: gene therapy
Target raw: fMRI - GE Medical System
Target normalized: fMRI - GE Medical System
NCT06752252Source recordAI-normalized
Ultrasound Guided Paravertebral Block Versus Erector Spinae Plane Block for Postoperative Analgesia After Inguinal Hernia Repair in Pediatric Patients: a Randomized Clinical Trial
The aim of the study is to compare postoperative analgesia in pediatric patients undergoing inguinal hernia repair by comparing the efficacy of ultrasound guided paravertebral block versus ultrasound guided erector spinae plane block.
AI analysis
Indication: Analgesia, Postoperative
Modality: gene therapy
Target: ultrasound guided paravertebral block, Ultrasound guided erector spinae plane block, control group C
Sponsor: Zagazig University
Source URL: ClinicalTrials.gov
Source updated: Jan 01, 2025
Ingested: Jun 09, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: gene therapy
View original source fields
Condition raw: Analgesia, Postoperative
Condition normalized: Analgesia, Postoperative
Modality raw: gene therapy
Modality normalized: gene therapy
Target raw: ultrasound guided paravertebral block, Ultrasound guided erector spinae plane block, control group C
Target normalized: ultrasound guided paravertebral block, Ultrasound guided erector spinae plane block, control group C
NCT06285643Source recordAI-normalized
A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson's Disease
AskBio Inc is conducting a Phase 2 clinical trial to evaluate the safety and efficacy of AAV2-GDNF gene therapy in adults with moderate Parkinson's Disease. The trial is randomized, double-blind, and sham-controlled, aiming to enroll approximately 127 participants across multiple sites in the U.S. and Germany.
AI analysis
Indication: Parkinson Disease
Modality: gene therapy
Target: AAV2-GDNF gene therapy for Parkinson's Disease
Sponsor: AskBio Inc
Source URL: ClinicalTrials.gov
Source updated: Dec 08, 2025
Ingested: May 31, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: gene therapy
View original source fields
Condition raw: Parkinson Disease
Condition normalized: Parkinson Disease
Modality raw: Parkinson Disease
Modality normalized: gene therapy
Target raw: AAV2-GDNF gene therapy for Parkinson's Disease
Target normalized: AAV2-GDNF gene therapy for Parkinson's Disease
NCT01658748Source recordAI-normalized
A Pilot Study to Examine Deep Brain Stimulation (DBS) in the Basolateral Nucleus (BLn) of the Amygdala for the Management of Symptoms in Veterans With Chronic and Treatment-Refractory Combat-related Post-Traumatic Stress Disorder (PTSD)
This pilot study aimed to evaluate the safety and efficacy of deep brain stimulation (DBS) targeting the basolateral nucleus of the amygdala in veterans with treatment-refractory PTSD. The study was sponsored by the US Department of Veterans Affairs and intended to recruit combat veterans suffering from severe PTSD symptoms despite existing treatment options.
AI analysis
Indication: Post Traumatic Stress Disorder
Modality: gene therapy
Target: Post-Traumatic Stress Disorder (PTSD)
Sponsor: US Department of Veterans Affairs
Source URL: ClinicalTrials.gov
Source updated: May 29, 2013
Ingested: May 30, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: gene therapy
View original source fields
Condition raw: Post Traumatic Stress Disorder
Condition normalized: Post Traumatic Stress Disorder
Modality raw: Post Traumatic Stress Disorder
Modality normalized: gene therapy
Target raw: Post-Traumatic Stress Disorder (PTSD)
Target normalized: Post-Traumatic Stress Disorder (PTSD)
NCT07389382Source recordAI-normalized
Effect of Three-Dimensional Educational Material Developed for Pain Mechanisms on Motivation and Knowledge Levels
This clinical trial, conducted by Zonguldak Bulent Ecevit University, aimed to evaluate the effectiveness of a 3D-printed biochemical activity model in enhancing nursing students' understanding of pain mechanisms and their motivation to learn. The study involved 90 nursing students divided into intervention and control groups, with the intervention group receiving training using the 3D model.
AI analysis
Indication: Pain Management
Modality: gene therapy
Target: Pain Management Education
Sponsor: Zonguldak Bulent Ecevit University
Source URL: ClinicalTrials.gov
Source updated: Feb 05, 2026
Ingested: May 30, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: gene therapy
View original source fields
Condition raw: Pain Management
Condition normalized: Pain Management
Modality raw: Pain Management
Modality normalized: gene therapy
Target raw: Pain Management Education
Target normalized: Pain Management Education
NCT03731845Source recordAI-normalized
Evaluation of Individual Sensitivity to the Gonadotoxicity of Chemotherapy in Young Patients With Breast Cancer
The ESIGON trial evaluates the genetic factors influencing ovarian reserve decline in young breast cancer survivors post-chemotherapy. With rising survival rates, understanding fertility preservation is crucial for improving quality of life in this demographic.
AI analysis
Indication: Breast Cancer
Modality: gene therapy
Target: Breast Cancer
Sponsor: Assistance Publique - Hôpitaux de Paris
Source URL: ClinicalTrials.gov
Source updated: Nov 20, 2025
Ingested: May 30, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: gene therapy
View original source fields
Condition raw: Breast Cancer
Condition normalized: Breast Cancer
Modality raw: Breast Cancer
Modality normalized: gene therapy
Target raw: Breast Cancer
Target normalized: Breast Cancer
NCT01811160Source recordAI-normalized
Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics
This clinical trial investigated the effects of melatonin on metabolic side effects in patients treated with second generation antipsychotics for schizophrenia or bipolar disorder. The study aimed to address the significant metabolic risks associated with SGA, which include weight gain and dysregulation of glucose and lipids.
AI analysis
Indication: Second Generation Antipsychotic Induced Metabolic Adverse Effects
Modality: gene therapy
Target: Metabolic disturbances associated with Second Generation Antipsychotics (SGA)
Sponsor: Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente
Source URL: ClinicalTrials.gov
Source updated: Mar 14, 2013
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: gene therapy
View original source fields
Condition raw: Second Generation Antipsychotic Induced Metabolic Adverse Effects
Condition normalized: Second Generation Antipsychotic Induced Metabolic Adverse Effects
Modality raw: Second Generation Antipsychotic Induced Metabolic Adverse Effects
Modality normalized: gene therapy
Target raw: Metabolic disturbances associated with Second Generation Antipsychotics (SGA)
Target normalized: Metabolic disturbances associated with Second Generation Antipsychotics (SGA)
NCT06457048Source recordAI-normalized
Evaluation of a Locally Adapted Stroke Unit to Improve Outcomes in Lusaka, Zambia
The Zambia Stroke Unit Study (ZASUS) aims to evaluate the effectiveness of a locally adapted stroke unit at the University Teaching Hospital in Lusaka, Zambia. The study focuses on improving stroke care outcomes through the implementation of evidence-based clinical practice guidelines tailored to the local context. The trial is sponsored by Johns Hopkins University in collaboration with the National Institutes of Health (NIH).
AI analysis
Indication: Stroke
Modality: gene therapy
Target: Stroke care improvement in Zambia
Sponsor: Johns Hopkins University
Source URL: ClinicalTrials.gov
Source updated: Sep 04, 2025
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: gene therapy
View original source fields
Condition raw: Stroke
Condition normalized: Stroke
Modality raw: Stroke
Modality normalized: gene therapy
Target raw: Stroke care improvement in Zambia
Target normalized: Stroke care improvement in Zambia
NCT05595096Source recordAI-normalized
Comparison of Thoracic Paravertebral Nerve Block Combined Laryngeal Mask Airway With Preservation of Spontaneous Breathing Versus General Anesthesia Using Double-lumen Endobronchial Intubation in Patients Undergoing Thoracoscopic Surgery:
This clinical trial evaluates the efficacy of non-intubation anesthesia versus traditional intubation anesthesia in enhancing recovery for patients undergoing thoracoscopic surgery. The study was conducted by Zhenjiang First People's Hospital and involved 59 patients, focusing on postoperative outcomes such as hospital stay and complications.
AI analysis
Indication: Thoracoscopic Surgery
Modality: gene therapy
Target: Thoracoscopic Surgery
Sponsor: Zhenjiang First People's Hospital
Source URL: ClinicalTrials.gov
Source updated: Oct 26, 2022
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: gene therapy
View original source fields
Condition raw: Thoracoscopic Surgery
Condition normalized: Thoracoscopic Surgery
Modality raw: Thoracoscopic Surgery
Modality normalized: gene therapy
Target raw: Thoracoscopic Surgery
Target normalized: Thoracoscopic Surgery
NCT07343336Source recordAI-normalized
FENUA-METABOGOUT : Genetic Landscape of Gout, Inflammation and Metabolic Diseases in French Polynesia.
FENUA-METABOGOUT : Genetic Landscape of Gout, Inflammation and Metabolic Diseases in French Polynesia. is a registry-stage clinical asset sponsored by Lille Catholic University in Gout Disease, Metabolic Diseases, Inflammation. SEO and diligence focus: Epidemiological study, Blood and urine tests, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
AI analysis
Indication: Gout Disease
Modality: gene therapy
Target: Epidemiological study, Blood and urine tests
Sponsor: Lille Catholic University
Source URL: ClinicalTrials.gov
Source updated: Jan 15, 2026
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: gene therapy
View original source fields
Condition raw: Gout Disease
Condition normalized: Gout Disease
Modality raw: chronic kidney disease obesity
Modality normalized: gene therapy
Target raw: Epidemiological study, Blood and urine tests
Target normalized: Epidemiological study, Blood and urine tests
NCT01839084Source recordAI-normalized
Impact of Xenon-anesthesia on the Renal Function After Partial Nephrectomy - PaNeX: Partial Nephrectomy Under Xenon:a Pilot Study
Purpose of this study is to determine whether Xenon - as compared to Isoflurane - shows a nephroprotection after partial nephrectomy.
AI analysis
Indication: Renal Function After Partial Nephrectomy
Modality: gene therapy
Target: Xenon, Isoflurane
Sponsor: RWTH Aachen University
Source URL: ClinicalTrials.gov
Source updated: Feb 18, 2016
Ingested: May 22, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: gene therapy
View original source fields
Condition raw: Renal Function After Partial Nephrectomy
Condition normalized: Renal Function After Partial Nephrectomy
Modality raw: gene therapy
Modality normalized: gene therapy
Target raw: Xenon, Isoflurane
Target normalized: Xenon, Isoflurane
NCT05785195Source recordAI-normalized
Study on the Mechanism of Inhaled Nitric Oxide in the Treatment of Patients With Chronic Obstructive Pulmonary Disease (COPD) Complicated With Pulmonary Hypertension
There is a lack of effective treatments for chronic obstructive pulmonary disease (COPD) complicated with pulmonary hypertension. Previous studies have found that inhaled nitric oxide (iNO) can reduce pulmonary artery pressure and improve exercise capacity in COPD with pulmonary hypertension patients. However, the specific mechanism is unclear. The study aims to evaluate pulmonary ventilation/perfusion, pulmonary artery pressure, oxygenation, symptoms and quality of life in COPD with pulmonary hypertension patients after short-term treatment with iNO. Observing a series of pathophysiological changes caused by the treatment of pulmonary hypertension with iNO in COPD, the investigators hope to provide new theoretical basis and research ideas.
AI analysis
Indication: Chronic Obstructive Pulmonary Disease
Modality: gene therapy
Target: Nitric Oxide Generation and Delivery System
Sponsor: Ting YANG
Source URL: ClinicalTrials.gov
Source updated: May 15, 2023
Ingested: May 21, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by modality_normalized: gene therapy
View original source fields
Condition raw: Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension
Condition normalized: Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension
Modality raw: gene therapy
Modality normalized: gene therapy
Target raw: Nitric Oxide Generation and Delivery System
Target normalized: Nitric Oxide Generation and Delivery System